6.68

3.33% -0.23

Eupraxia Pharmaceuticals Inc (EPRX)

Overview News Price History Discussions Forecast

Eupraxia Pharmaceuticals Inc stock is traded at $6.68, with a volume of 245.32K. It is down -3.33% in the last 24 hours and up +12.84% over the past month. Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Previous Close:

$6.91

Open:

$7.01

24h Volume:

245.32K

Relative Volume:

0.86

Market Cap:

$436.38M

Revenue:

Net Income/Loss:

$-44.47M

P/E Ratio:

-6.5612

EPS:

-1.0181

Net Cash Flow:

$-33.50M

1W Performance:

-0.15%

1M Performance:

+12.84%

6M Performance:

-17.73%

1Y Performance:

+18.89%

1-Day Range:

$6.60

$7.03

1-Week Range:

$6.36

$7.11

52-Week Range:

$4.88

$9.32

Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile

Name

Eupraxia Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

EPRX's Discussions on Twitter

Compare EPRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EPRX Eupraxia Pharmaceuticals Inc	6.68	436.38M	0	-44.47M	-33.50M	-1.0181
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Initiated	William Blair	Outperform
Jul-24-25	Initiated	Cantor Fitzgerald	Overweight
Jun-26-25	Initiated	H.C. Wainwright	Buy
Jun-16-25	Initiated	Canaccord Genuity	Speculative Buy
Feb-21-25	Initiated	Craig Hallum	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy

View All

Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News

Jul 10, 2026

Why Eupraxia Pharmaceuticals Inc stock is tanking today - Wealth Awesome

Jul 10, 2026

Jul 07, 2026

Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances - TipRanks

Jul 07, 2026

Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board - Stock Titan

Jul 07, 2026

Eupraxia Pharmaceuticals appoints three directors to board - Investing.com

Jul 07, 2026

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization - Investing News Network

Jul 07, 2026

Eupraxia Pharmaceuticals appoints three directors to board By Investing.com - Investing.com Australia

Jul 07, 2026

Jul 03, 2026

EPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jul 03, 2026

Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com - Investing.com Nigeria

Jun 25, 2026

Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (FWB:X43) - TradingView

Jun 25, 2026

Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17 - Moomoo

Jun 25, 2026

X43 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Price to sales forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView

Jun 25, 2026

Price to earnings forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Eupraxia Pharmaceuticals, Inc. – TSX:EPRX - TradingView

Jun 25, 2026

Jun 24, 2026

Eupraxia Pharmaceuticals (EPRX) Slips 2.19% as Stock Tests Key Support at $5.94Shakeout Pattern - dars.gov.et

Jun 24, 2026

Jun 23, 2026

Eupraxia Pharmaceuticals (EPRX) Stock Analysis Report | Financials & Insights - Benzinga

Jun 23, 2026

Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome

Jun 23, 2026

Jun 22, 2026

Eupraxia Pharmaceuticals Shareholders Back Board Slate and Auditor at June 18 AGM - TipRanks

Jun 22, 2026

Form 6K Eupraxia Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Strong support as Eupraxia (NASDAQ: EPRX) shareholders elect seven directors, renew KPMG - Stock Titan

Jun 22, 2026

Jun 19, 2026

Eupraxia Pharmaceuticals elects all seven board nominees and reappoints KPMG as auditor at AGM. - Pluang

Jun 19, 2026

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - The Manila Times

Jun 19, 2026

Eupraxia shareholders back all 7 directors at annual meeting - Stock Titan

Jun 19, 2026

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders - GlobeNewswire Inc.

Jun 19, 2026

Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome

Jun 19, 2026

Jun 18, 2026